Abstract

Cryptococcal meningoencephalitis represents a serious infection of the central nervous system, where reliable prognostic factors during the disease course are needed. Twenty-one patients diagnosed with cryptococcal meningoencephalitis in a German university hospital from 1999 to 2013 were analysed retrospectively. CSF parameters were analysed prior to therapy and during antifungal treatment and were compared between patients who survived or deceased. Fifteen patients clinically improved after antifungal therapy, while six patients died. No differences were observed between the outcome groups for the CSF parameters cell count, lactate, total protein, and CSF-serum albumin quotients (QAlb). Follow-up examinations of serum cryptococcal antigen titer and CSF cell count have shown that these parameters cannot be used to monitor the efficacy of antifungal therapy as well. In contrast, the course of QAlb during therapy was indicative for the outcome as a possible prognostic marker. In patients with clinical improvement QAlb values were falling under therapy, while rising QAlb values were found in patients with fatal outcome indicating a continuing dysfunction of the blood-CSF barrier. In conclusion, our results indicate that, among the various CSF parameters, the course of QAlb presents a promising marker that might be used to monitor the efficacy of antifungal therapy.

Highlights

  • Cryptococcal meningoencephalitis presents a serious lifethreatening infection of the central nervous system (CNS) in patients with both intact and compromised immune system [1]

  • Seventeen patients suffered from HIV infection as a predisposing factor for cryptococcal meningitis

  • Seven had been diagnosed with HIV before the presentation of cryptococcal meningitis, but only two patients were treated with antiretroviral therapy (ART) at admission

Read more

Summary

Introduction

Cryptococcal meningoencephalitis presents a serious lifethreatening infection of the central nervous system (CNS) in patients with both intact and compromised immune system [1]. It is a common opportunistic infection and AIDSdefining illness in patients with HIV infection. Before the highly active antiretroviral therapy (HAART) era, the prevalence of AIDS associated cryptococcal meningoencephalitis was 5–10% in the developed countries [2, 3]. Despite antiretroviral treatment and appropriate antifungal therapy, the mortality remains high even in the developed countries ranging from 10 to 30% [5,6,7]. Further strategies for improving the overall outcome are needed

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call